Skip to main content
    E

    Editas Medicine Inc (EDIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.87
    -0.30 (-13.82%)

    Market Cap: $334.92M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Editas Medicine Inc (EDIT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Editas Medicine (EDIT) to earn -$0.83 per share in the fiscal year ending Dec 31, 2026, on revenue of $29.39M. Of 13 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.62, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 69% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy969.2%
    Hold215.4%
    Sell00.0%
    Strong Sell215.4%
    Consensus
    Hold
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 32.5%.

    Fiscal year ending Dec 31, 2026
    -$0.83
    EPS consensus, revenue $29.39M
    Fiscal year ending Dec 31, 2027
    -$0.74
    EPS consensus, revenue $19.83M
    Next report
    Mar 8, 2027
    Confirmed, after the close

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.83-$0.95 to -$0.784$29.39M$27.00M to $33.63M5
    Dec 31, 2027-$0.74-$0.84 to -$0.606$19.83M$2.00M to $39.33M12

    Quarterly Estimates

    The EPS consensus falls from -$0.19 for the quarter ending Dec 31, 2026 to -$0.20 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.19-$0.27 to -$0.0814$6.76M$980000 to $21.00M14
    Mar 31, 2027-$0.20-$0.20 to -$0.201$3.13M$500000 to $6.41M3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 11 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202651
    Fiscal year ending Dec 31, 202751
    Quarter ending Mar 31, 202710

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.83-$0.83-$0.83-$0.83-$0.83N/A
    Fiscal year ending Dec 31, 2027-$0.74-$0.75-$0.75-$0.75-$0.75N/A
    Quarter ending Mar 31, 2027-$0.20-$0.30-$0.30-$0.30-$0.27N/A

    Frequently Asked Questions About EDIT

    What is the EDIT stock forecast?

    Consensus analyst estimates put Editas Medicine's EPS at -$0.83 for the fiscal year ending Dec 31, 2026, on revenue of $29.39M. The consensus rating from 13 analysts is Hold.

    How do analysts rate EDIT stock?

    Of 13 analysts covering Editas Medicine, 0 rate it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 2 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from EDIT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.83, with estimates from -$0.95 to -$0.78 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.74, with estimates from -$0.84 to -$0.60 from 6 analysts.

    What revenue do analysts expect from Editas Medicine next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $29.39M, with estimates from $27.00M to $33.63M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $19.83M, with estimates from $2.00M to $39.33M.

    How many analysts cover EDIT?

    13 analysts rate Editas Medicine stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.